Evidence map›Paper›PMID 26179360›Full record

ArticleDiabetic medicine : a journal of the British Diabetic Association2016

Severe hypoglycaemia in adults with insulin-treated diabetes: impact on healthcare resources.

S R Heller, B M Frier, M L Hersløv, J Gundgaard, S C L Gough

Open access · hybridAbstract readComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Diabetic medicine : a journal of the British Diabetic Association, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
37citing papers in PubMed, 1 pooled it
6.3field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

37 citing papers in PubMed, 1 synthesis or guideline pooled it, 81 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Trial
  5. Trial
  6. Trial
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Observational
  16. Article
  17. Article
  18. Observational
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 4 institutions in 2 countries.

S R HellerAcademic Unit of Diabetes, Endocrinology and Metabolism, University of Sheffield, Sheffield, UK.
B M FrierThe Queen's Medical Research Institute, University of Edinburgh, Edinburgh, UK.
M L HersløvMedical & Science, Novo Nordisk A/S, Søborg, Denmark.
J GundgaardHealth Economics & HTA, Novo Nordisk A/S, Søborg, Denmark.
S C L GoughOxford Centre for Diabetes Endocrinology and Metabolism, Academic Health Science Network, NIHR Oxford Biomedical Research Centre, University of Oxford, Oxford, UK.
Novo Nordisk (Denmark) · DKOxford Centre for Diabetes, Endocrinology and Metabolism · GBThe Queen's Medical Research Institute · GBUniversity of Sheffield · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimsTo assess resource utilization associated with severe hypoglycaemia across three insulin regimens in a large phase 3a clinical programme involving people with Type 1 diabetes treated with basal-bolus insulin, people with Type 2 diabetes treated with multiple daily injections and people with Type 2 diabetes treated with basal-oral therapy.

methodsData relating to severe hypoglycaemia events (defined as episodes requiring external assistance) from the insulin degludec and insulin degludec/insulin aspart programme (15 trials) were analysed using descriptive statistics. Comparators included insulin glargine, biphasic insulin aspart, insulin detemir and sitagliptin. Mealtime insulin aspart was used in some regimens. This analysis used the serious adverse events records, which documented the use of ambulance/emergency teams, a hospital/emergency room visit ≤ 24 h, or a hospital visit > 24 h.

resultsIn total, 536 severe hypoglycaemia events were analysed, of which 157 (29.3%) involved an ambulance/emergency team, 64 (11.9%) led to hospital/emergency room attendance of ≤ 24 h and 36 (6.7%) required hospital admission (> 24 h). Although there were fewer events in people with Type 2 diabetes compared with Type 1 diabetes, once a severe episode occurred, the tendency to utilize healthcare resources was higher in Type 2 diabetes vs. Type 1 diabetes. A higher proportion (47.6%) in the basal-oral therapy group required hospital treatment for > 24 h versus the Type 1 diabetes (5.0%) and Type 2 diabetes multiple daily injections (5.3%) groups.

conclusionThis analysis suggests that severe hypoglycaemia events often result in emergency/ambulance calls and hospital treatment, incurring a substantial health economic burden, and were associated with all insulin regimens.

Indexed as

Administration, OralAdultClinical Trials, Phase III as TopicCohort StudiesCosts and Cost AnalysisDiabetes Mellitus, Type 1Diabetes Mellitus, Type 2Dipeptidyl-Peptidase IV InhibitorsDrug Administration ScheduleDrug CombinationsDrug Therapy, CombinationHealth Care CostsHumansHypoglycemiaHypoglycemic AgentsInsulin AspartDipeptidyl-Peptidase IV InhibitorsDrug CombinationsHypoglycemic AgentsInsulin Aspartinsulin degludecinsulin degludec, insulin aspart drug combinationInsulin DetemirInsulin GlargineInsulin, Long-ActingSitagliptin Phosphate

Identifiers

PMID26179360
PMCPMC5034744
OpenAlexW1494818682

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.